Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy iBio stock
Own iBio stock in just a few minutes.
iBio, Inc is a biotechnology business based in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. iBio employs 55 staff and has a trailing 12-month revenue of around USD$1.3 million.
How to buy shares in iBio
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for iBio Find the stock by name or ticker symbol: IBIO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iBio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of iBio, depending on your broker.
- Check in on your investment. Congratulations, you own a part of iBio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
iBio share price
Use our graph to track the performance of IBIO stocks over time.iBio shares at a glance
Information last updated 2020-09-25.
| 52-week range | USD$0.05 - USD$7.45 |
|---|---|
| 50-day moving average | USD$2.4026 |
| 200-day moving average | USD$2.0165 |
| Wall St. target price | USD$3.1 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.943 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy iBio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
iBio price performance over time
Historical closes compared with the last close of $N/A
| 1 week (2020-09-17) | -100.00% |
|---|---|
| 1 month (2020-08-27) | -100.00% |
| 3 months (2020-06-26) | -100.00% |
| 6 months (2020-03-27) | -100.00% |
| 1 year (2019-09-27) | -100.00% |
|---|---|
| 2 years (2018-09-27) | -100.00% |
| 3 years (2017-09-27) | -100.00% |
| 5 years (2015-09-25) | -100.00% |
iBio financials
| Revenue TTM | USD$1.3 million |
|---|---|
| Gross profit TTM | USD$2 million |
| Return on assets TTM | -23.99% |
| Return on equity TTM | -320.62% |
| Profit margin | 0% |
| Book value | $0.037 |
| Market capitalisation | USD$336.6 million |
TTM: trailing 12 months
Shorting iBio shares
There are currently 16.0 million iBio shares held short by investors – that's known as iBio's "short interest". This figure is 73.6% up from 9.2 million last month.
There are a few different ways that this level of interest in shorting iBio shares can be evaluated.
iBio's "short interest ratio" (SIR)
iBio's "short interest ratio" (SIR) is the quantity of iBio shares currently shorted divided by the average quantity of iBio shares traded daily (recently around 34.8 million). iBio's SIR currently stands at 0.46. In other words for every 100,000 iBio shares traded daily on the market, roughly 460 shares are currently held short.
However iBio's short interest can also be evaluated against the total number of iBio shares, or, against the total number of tradable iBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iBio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 iBio shares in existence, roughly 90 shares are currently held short) or 0.112% of the tradable shares (for every 100,000 tradable iBio shares, roughly 112 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iBio.
Find out more about how you can short iBio stock.
iBio share dividends
We're not expecting iBio to pay a dividend over the next 12 months.
Have iBio's shares ever split?
iBio's shares were split on a 1:10 basis on 11 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.
iBio share price volatility
Over the last 12 months, iBio's shares have ranged in value from as little as $0.05 up to $7.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -5.9482. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.
iBio overview
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Frequently asked questions
Ask an Expert